Rensselaer Polytechnic Institute (RPI)

In Cell Studies, Seaweed Extract Outperforms Remdesivir in Blocking COVID-19 Virus

Heparin, a common anitcoagulent, could also form basis of a viral trap for SARS-CoV-2

Newswise — TROY, N.Y. — In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease. Heparin, a common blood thinner, and a heparin variant stripped of its anticoagulant properties, performed on par with remdesivir in inhibiting SARS-CoV-2 infection in mammalian cells.

Published online today in Cell Discovery, the research is the latest example of a decoy strategy researchers from the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselear Polytechnic Institute are developing against viruses like the novel coronavirus that spawned the current global health crisis.

The spike protein on the surface of SARS-CoV-2 latches onto the ACE-2 receptor, a molecule on the surface of human cells. Once secured, the virus inserts its own genetic material into the cell, hijacking the cellular machinery to produce replica viruses. But the virus could just as easily be persuaded to lock onto a decoy molecule that offers a similar fit. The neutralized virus would be trapped and eventually degrade naturally.

Previous research has shown this decoy technique works in trapping other viruses, including dengue, Zika, and influenza A. To hear the researchers discuss their findings, watch this video.

“We’re learning how to block viral infection, and that is knowledge we are going to need if we want to rapidly confront pandemics,” said Jonathan Dordick, the lead researcher and a professor of chemical and biological engineering at Rensselaer Polytechnic Institute. “The reality is that we don’t have great antivirals. To protect ourselves against future pandemics, we are going to need an arsenal of approaches that we can quickly adapt to emerging viruses.” 

The Cell Discovery paper tests antiviral activity in three variants of heparin (heparin, trisulfated heparin, and a non-anticoagulant low molecular weight heparin) and two fucoidans (RPI-27 and RPI-28) extracted from seaweed. All five compounds are long chains of sugar molecules known as sulfated polysaccharides, a structural conformation that the results of a binding study published earlier this month in Antiviral Research suggested as an effective decoy.

The researchers performed a dose response study known as an EC50 — shorthand for the effective concentration of the compound that inhibits 50% of viral infectivity — with each of the five compounds on mammalian cells. For the results of an EC50, which are given in a molar concentration, a lower value signals a more potent compound.

RPI-27 yielded an EC50 value of approximately 83 nanomolar, while a similar previously published and independent in vitro test of remdesivir on the same mammalian cells yielded an EC50 of 770 nanomolar. Heparin yielded an EC50 of 2.1 micromolar, or about one-third as active as remdesivir, and a non-anticoagulant analog of heparin yielded an EC50 of 5.0 micromolar, about one-fifth as active as remdesivir.

A separate test found no cellular toxicity in any of the compounds, even at the highest concentrations tested.

 “What interests us is a new way of getting at infection,” said Robert Linhardt, a Rensselaer professor of chemistry and chemical biology who is collaborating with Dordick to develop the decoy strategy. “The current thinking is that the COVID-19 infection starts in the nose, and either of these substances could be the basis for a nasal spray. If you could simply treat the infection early, or even treat before you have the infection, you would have a way of blocking it before it enters the body.”

Dordick added that compounds from seaweed “could serve as a basis for an oral delivery approach to address potential gastrointestinal infection.” 

In studying SARS-CoV-2 sequencing data, Dordick and Linhardt recognized several motifs on the structure of the spike protein that promised a fit compatible with heparin, a result borne out in the binding study. The spike protein is heavily encrusted in glycans, an adaptation that protects it from human enzymes which could degrade it, and prepares it to bind with a specific receptor on the cell surface.

“It’s a very complicated mechanism that we quite frankly don’t know all the details about, but we’re getting more information,” said Dordick. “One thing that’s become clear with this study is that the larger the molecule, the better the fit. The more successful compounds are the larger sulfated polysaccharides that offer a greater number of sites on the molecules to trap the virus.” 

Molecular modeling based on the binding study revealed sites on the spike protein where the heparin was able to interact, raising the prospects for similar sulfated polysaccharides. 

“This exciting research by Professors Dordick and Linhardt is among several ongoing research efforts at CBIS, as well as elsewhere at Rensselaer, to tackle the challenges of the COVID-19 pandemic through novel therapeutic approaches and the repurposing of existing drugs,” said CBIS Director Deepak Vashishth.

Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro” was published in Cell Discovery with the support of the National Research Foundation of Korea. At Rensselaer, Dordick and Linhardt were joined in the research by Paul S. Kwon, Seok-Joon Kwon, Weihua Jin, Fuming Zhang, and Keith Fraser, and by researchers at the Korea Research Institute of Bioscience and Biotechnology in Cheongju, Republic of Korea, and Zhejiang University of Technology in Hangzhou, China.

About Rensselaer Polytechnic Institute

Founded in 1824, Rensselaer Polytechnic Institute is America’s first technological research university. Rensselaer encompasses five schools, 32 research centers, more than 145 academic programs, and a dynamic community made up of more than 7,900 students and over 100,000 living alumni. Rensselaer faculty and alumni include more than 145 National Academy members, six members of the National Inventors Hall of Fame, six National Medal of Technology winners, five National Medal of Science winners, and a Nobel Prize winner in Physics. With nearly 200 years of experience advancing scientific and technological knowledge, Rensselaer remains focused on addressing global challenges with a spirit of ingenuity and collaboration. To learn more, please visit www.rpi.edu.

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 3408
Newswise: Last-resort life support option helped majority of critically ill COVID-19 patients survive, global study shows
24-Sep-2020 3:20 PM EDT
Last-resort life support option helped majority of critically ill COVID-19 patients survive, global study shows
Michigan Medicine - University of Michigan

It saved lives in past epidemics of lung-damaging viruses. Now, the life-support option known as ECMO appears to be doing the same for many of the critically ill COVID-19 patients who receive it. Patients in a new international study faced a staggeringly high risk of death, as ventilators failed to support their lungs. But after they were placed on ECMO, their actual death rate was less than 40%.

Released: 25-Sep-2020 4:15 PM EDT
Faced with pandemic shortages, researchers combine heat and humidity to disinfect N95 masks for reuse
SLAC National Accelerator Laboratory

They found that gently heating N95 masks in high relative humidity could inactivate SARS-CoV-2 virus trapped within the masks, without degrading the masks’ performance.

Released: 25-Sep-2020 3:30 PM EDT
Team assessing if dual-antibody injection prevents COVID-19 illness
University of Texas Health Science Center at Houston

A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.

Released: 25-Sep-2020 2:30 PM EDT
Yes, Wisconsin Republicans have the power to overturn the extended mask mandate order by Governor Evers
Newswise

Republicans have the legal power to reverse the order by Wisconsin Governor Tony Evers that extends the mask mandate.

Released: 25-Sep-2020 1:55 PM EDT
How do Americans view the virus? Anthropology professor examines attitudes of COVID
Northern Arizona University

In her ongoing research about Americans' responses to the COVID-19 pandemic, Northern Arizona University anthropology professor Lisa Hardy and her collaborators have talked to dozens of people.

Released: 25-Sep-2020 12:55 PM EDT
During pandemic, racism puts additional stress on Asian Americans
Massachusetts General Hospital

Many people are feeling anxious during these uncertain times as they navigate the risks associated with COVID-19 and experience the tension from physical distancing or isolation for what can seem like an eternity.

Released: 25-Sep-2020 12:55 PM EDT
COVID-19 shapes political approval ratings
University of North Carolina at Chapel Hill

Approval ratings of political leaders surged in the early days of the COVID-19 pandemic, according to a new study published in the Proceedings of the National Academy of Sciences.

Released: 25-Sep-2020 12:40 PM EDT
ASU Researchers Receive $6m State Contract to Develop Rapid, 20-Minute Covid-19 Saliva Test
Arizona State University (ASU)

As the world manages through the coronavirus pandemic, Arizona State University continues its work to discover and develop easier and more widespread COVID-19 testing to assist in managing the virus.

Released: 25-Sep-2020 11:55 AM EDT
Scholars untangle marketing's complex role in understanding political activities
American Marketing Association (AMA)

As 2020 began, many pundits predicted a politically charged year, but few predicted that it would include a global pandemic overtaxing healthcare resources, strained U.S. race relations resulting in mass demonstrations across the globe, devastating fires consuming massive swaths of the United States, and a catastrophic global economic downturn.

Released: 25-Sep-2020 10:50 AM EDT
COVID-19 Spurs Anxious, Upsetting Dreams
American Psychological Association (APA)

The anxiety, stress and worry brought on by COVID-19 is not limited to daytime hours. The pandemic is affecting our dreams as well, infusing more anxiety and negative emotions into dreams and spurring dreams about the virus itself, particularly among women, according to research published by the American Psychological Association.


Showing results

110 of 3408

close
0.94362